• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development

    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    MPO's Most Read Stories This Week—June 25

    Magnetic Insight Announces $17 Million in Series B Funding

    BreatheSuite Adds Brad Fluegel to its Board

    Labcorp Launches At-Home Collection Device for Diabetes Risk Testing

    Thirona, Free Flow Medical Partner on COPD Solutions
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development

    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Theranos Fraud Trial, Part II: The Blame Game Continues

    An Update on Surgical Robotics

    Letting the Light In: How Failure Analysis is the Cornerstone of Success

    Three Talent Strategies to Attract High-Demand Skills

    The Advantages of Bioburden Screening for Sterilization Validation
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    BMP Medical

    Trademark Plastics Inc.

    Fusion Biotec Inc.

    Cirtec Medical

    Arthur G. Russell Co. Inc., The
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    The Power of Leveraging Customer Relationships

    Cost Effective & Efficient Wire EDM Techniques

    How MedTech Professionals Can Help Combat Physician Burnout

    How to Optimize Manufacturing Lines and Choose Which Machines to Buy

    How Are Hypodermic Needles Made?
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    BMP Medical

    Trademark Plastics Inc.

    Fusion Biotec Inc.

    Cirtec Medical

    Arthur G. Russell Co. Inc., The
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    The End of EUA Is Coming Soon

    How to prepare for the transition back to normal for medical devices in 2022.

    The End of EUA Is Coming Soon
    Jon Speer, Founder and VP of QA/RA at Greenlight Guru01.07.22
    Yes, we should all realize that the FDA’s Emergency Use Authorization (EUA) for the medical device industry is definitely going to end sometime soon. No, I’m not able to tell you for certain or even predict with any accuracy as to exactly when. 
     
    Here is what I do know about the status of EUA. The FDA is starting to hint that an EUA transition will be happening before too long. FDA has stated that they expect there to be a gradual transition back to normal for medical devices in 2022. Additionally, the FDA recently published two draft guidances regarding COVID-19 transition:
     
    • Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency
    • Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency
     
    Just in case you are not familiar, EUA is a provision that allows the FDA to help address public health against chemical, biological, radiological, nuclear, and infectious disease threats. Of course, the COVID-19 pandemic fits within the latter of these. And in March 2020, the HHS Secretary declared that COVID-19 had reached the point where implementing EUA became necessary. Without getting into all the technical details, EUA is a temporary regulatory pathway to authorize the use of drugs, biologics, medical devices, etc. to address needs of the pandemic. 
     
    Note the word authorize. Speaking for medical devices, there are typically 7 FDA pathways to bring a device to market. Without going through them all, the most common of these pathways is 510(k) clearance, premarket approval, and de novo granted. While it may seem a bit nitpicky, the differences between “clearance”, “approval”, and “granted” have very meaningful and important distinctions. And realize that an EUA is none of these pathways; it is a temporary authorization for use for a very specific use, in these times 100% specific to COVID-19. 
     
    With EUA, many of the typical expectations, regulations, and compliance requirements have either been lifted or much more lax than non-EUA processes. From an FDA FAQ page regarding COVID-19 EUA:

    • What is an emergency use authorization and how is being used to respond to COVID-19?
    •  
    • In certain types of emergencies, the FDA can issue an emergency use authorization, or EUA, to provide more timely access to critical medical products (including medicines and tests) that may help during the emergency when there are no adequate, approved, and available alternative options.
    •  
    • The EUA process is different than FDA approval, clearance, or licensing because the EUA standard may permit authorization based on significantly less data than would be required for approval, clearance, or licensing by the FDA. This enables the FDA to authorize the emergency use of medical products that meet the criteria within weeks rather than months to years. 
    •  
    • EUAs are in effect until the emergency declaration ends but can be revised or revoked as we evaluate the needs during the emergency and new data on the product’s safety and effectiveness, or as products meet the criteria to become approved, cleared, or licensed by the FDA.
     
    Specifically, note the underlined verbiage from the FDA. Also note that the intent behind EUA is to allow the FDA to authorize use of medical devices within weeks. The typical FDA regulatory pathways definitely take many months to several years. 
     
    Additionally, the barriers to entry for companies developing EUA products is much more lax as well. Typical activities such as documenting design controls for the development of a medical device, good manufacturing practices (GMPs), post-market surveillance, and quality system requirements are waived for EUAs. 
     
    Personally, I have some mixed feelings about the overall EUA process. On one hand, it is encouraging that the FDA is able to institute a fast path to get products into the marketplace that address an immediate health need. On the other hand, is it a good idea to remove the majority of medical device regulations for EUAs with no requirement or plan to address these?
     
    One other thing that is somewhat irksome with respect to EUAs, at least to me: I’ve heard quite a few folks in the media make statements about EUAs being just as safe and effective as non-EUA medical devices. This is just not a true statement across the board. I’m sure there are plenty of EUAs which are just as safe. And I’m also 100% sure there are hundreds of EUAs that can not make these sorts of claims. Why not? Remember, EUAs are not required to demonstrate the same level of safety and efficacy. 
     
    It’s been known since day one of EUA that these device market authorizations would be temporary and only applicable until HHS Secretary deems otherwise. It also should be known that if a company with EUA products plans to continue to sell and market the devices after the EUA termination date, that they must prepare traditional regulatory submissions (e.g. de novo, 510(k), PMA) and receive the appropriate permission from the FDA to keep the products on the market. Additionally, EUA product companies must address the previously relaxed regulations for design controls, GMPs, post-market surveillance, and quality systems. 
     
    Yes, the FDA has stated there will be a 6-month transition from when FDA announces the “EUA termination date.” However, if a company waits until the FDA announces the EUA termination date, six months will not be enough time for the company to do what is required to keep the products on the market. Simple translation: EUA devices that have not been "converted" to traditional medical devices via traditional regulatory pathways will need to be removed from the market.
     
    And there have been several hundred EUAs authorized by the FDA. Hundreds! 

    What to Do if You’re a Company with EUA Products

    What if you are a company with EUA products? What should you be doing now? 
     
    At the time of this post, the FDA has not yet announced the EUA termination date. So, you have in excess of six months to take action and address the normal medical device regulatory expectations. 
     
    My first piece of advice is that you conduct a gap analysis of your current EUA product and related documentation against what would typically be required for this type of medical device. Identifying the gaps will help determine what work will be required. The results of a gap analysis should help inform your regulatory strategy. For example, what regulatory pathway(s) should you pursue and why? More specifically: Should you pursue a de novo for your product? Or maybe a 510(k)? (Hopefully you get the point.)
     
    Understanding the gaps and devising your regulatory strategy is key because it will help you determine what you need to do and provide a relative idea of the timeline to address the needs. 
     
    Let me try a paint an even more specific picture of you. The majority of medical devices in the U.S. are Class II and require a 510(k) submission and market clearance from FDA. A typical timeline for receiving 510(k) market clearance is roughly six to nine months from after the date you submit it to the FDA. To get a device to the point of being ready for a 510(k) submission can easily be years. 
     
    I’ve also heard some anecdotes from colleagues and consultants that they have clients with EUA products who are simply planning to submit the same data and information for their product that they used for their EUA submission. Let me be blunt: This is not going to pass muster. This is a terrible approach and plan. Your EUA was specific to a COVID-19 indication. Upon EUA termination date, your product indications must be different than COVID-19 specific. 
     
    If you have EUA products in the market, you may have read my thoughts as a sort of doom and gloom. My purpose for writing this is to help articulate, illustrate, and educate you on some of what you need to know and be doing to continue selling your EUA products after the EUA termination date. 
     
    Remember, too, that if you have not established a quality management system (QMS) that complies with FDA 21 CFR Part 820, then this is also mission critical for your company. 
     

    Jon Speer is the founder and VP of QA/RA at Greenlight Guru a medical device quality management MDQMS software & a medical device guru with over 20 years of industry experience. Speer knows the best medical device companies in the world use quality as an accelerator. That's why he created Greenlight Guru to help companies move beyond compliance to achieve True Quality. 
     

    Trending
    • The Power Of Leveraging Customer Relationships
    • Intermountain Healthcare & Siemens Healthineers Open 3 Tellica Outpatient Imaging Centers
    • 5 Ways Plastics Revolutionized The Healthcare Industry
    • Magnetic Insight Announces $17 Million In Series B Funding
    • NHS England Selects Spectra Optia Apheresis System To Treat Sickle Cell Disease
    Breaking News
    • MPO's Most Read Stories This Week—June 25
    • Magnetic Insight Announces $17 Million in Series B Funding
    • BreatheSuite Adds Brad Fluegel to its Board
    • Labcorp Launches At-Home Collection Device for Diabetes Risk Testing
    • Thirona, Free Flow Medical Partner on COPD Solutions
    View Breaking News >
    CURRENT ISSUE

    June 2022

    • OEMs Seek Molders Offering Timely Techniques
    • Robotic Surgery: Cutting Through to the Latest
    • Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Florida Food Products Acquires Javo
    Roquette Launches Nutralys Rice Protein
    New IADSA Chair Lauds Explorations of Supplementation in Healthcare Policy
    Coatings World

    Latest Breaking News From Coatings World

    The Southern Society for Coatings Technology's 84th Annual Technical Conference A Success
    PPG to Showcase Specialty Automotive, Aerospace Adhesives, Sealants at Adhesives & Bonding Expo
    PPG’s New Paint for a New Start Initiative to Transform 25-plus Schools Worldwide
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most Read Stories This Week—June 25
    Magnetic Insight Announces $17 Million in Series B Funding
    BreatheSuite Adds Brad Fluegel to its Board
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pierre Fabre and Lonza Enter Manufacturing Agreement
    MasterControl and Elemental Machines Form Biomanufacturing Partnership
    Qosina Strengthens Aseptic Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Benefit Exec Joins Madison Reed's Board
    Peroni & Ellis Brooklyn Launch Fragrance Collection Inspired by Italian Spritz Cocktails
    Rhode Is Trending for June, Trendalytics Says
    Happi

    Latest Breaking News From Happi

    Wonder Curl Wins GlossWire's GlossPitch Competition
    Anti-aging Skincare Brand Vitabrid C12 Launches Bestsellers on Amazon
    Botanical Embedded Candles Can Be Fire Hazard, Says National Candle Association
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: INX’s VC Fund, Screen Industry and Ball Top This Week’s News
    British Coatings Federation Posts Online History
    Orion Announces Price Increases, Reduced Payment Terms
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    PCMC teams with IGT, Fujifilm makes big announcement and more
    Loftware recognized as 'AIDC Company of the Year'
    Schreiner MediPharm highlights sustainability of Needle-Trap technology
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Tranzonic Names VP of Supply Chain
    Ontex Climate Action Targets Approved by Science-Based Targets Initiative
    Suominen Test Center Assesses Biodegradability of Nonwovens
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—June 25
    3Spine Inc. Receives IDE Approval for U.S. Pivotal Clinical Trial
    Volume-Based Procurement to Reduce Chinese Orthopedic Market Value
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories
    NREL Names Jennifer Logan to Leadership Team as CFO
    National Grid Renewables Orders 2 GW of First Solar Modules

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login